Saturday, November 21, 2026 · Edition updated 6:00 AM ETSAT, NOV 21 · 6 AM ET editionNext edition in Next --:--:--

A skin serum showed visible improvements in older women over 12 weeks

A clinical trial in people · Journal of drugs in dermatology : JDD · Sep 4, 2026

What this means

Women aged 45 and older used a facial serum twice a day for 12 weeks. Experts and participants saw changes in fine lines, wrinkles, and skin hydration. This study had no comparison group, so it cannot show the serum caused the changes.

Plain-English summary written by an AI model from the abstract. The original is below.

Tested inPeople
Who it was tested in
Healthy women aged 45 and older with signs of skin aging
Kind of research
A clinical trial in people

The science

Original title
Clinical Evidence of Skin Improvements With a Biologically Active Multimodal Topical Skin Treatment.
Authors
Obagi ZE, Balian RJ, Ramsey SV et al.
Journal
Journal of drugs in dermatology : JDD
Published
Sep 4, 2026
Study type
Clinical trial · in humans

Abstract

Background

Antiaging skin treatments are continuously in development to meet the needs of an aging population and counteract cosmetic effects of glucagon-like peptide-1 receptor agonists. Peptide Facial Refining Concentrate (ST26-PF-F1) serum contains multiple bioactive peptides within a penetrative delivery system. A clinical study of ST26-PF-F1 assessed its effects on skin health/appearance and tolerability/usability.

What they did

This noncomparative 12-week study enrolled healthy females aged 45 years or older, Fitzpatrick phototypes I–VI, with evidence of skin aging. Participants applied ST26-PF-F1 twice daily. Efficacy (expert evaluation, instrumental measurements, confocal microscopy, and participant self-assessments) and tolerability/safety (dermatologist and participant reporting) were assessed at weeks 2, 4, 8, and 12.

What they found

Statistically significant improvements from baseline were observed for expert evaluator global assessments of fine lines, skin elasticity and plumpness, and facial contour and facial sagging (all time points); and wrinkles and skin firmness (weeks 4, 8, and 12). Significant improvements were also observed in skin hydration and elasticity (all time points); wrinkle volume, depth, and skin texture (weeks 4, 8, and 12); and lifting effect and V-shape (week 12). Confocal microscopy showed statistically significant improvements in interkeratinocyte brightness, papilla morphology, and dermal collagen fibers at weeks 4 and 12 and surface uniformity and keratinocyte morphology at week 12. Participants reported skin improvements across multiple measures and overall product satisfaction. ST26-PF-F1 was well tolerated with no treatment-related stinging, itching, or discomforting sensations. Clinical, instrumental, and microscopy assessments of ST26-PF-F1 demonstrated wrinkle-modulating and filler-like effects, visibly more balanced-looking facial geometry, favorable tolerability, and user satisfaction.

The authors' abstract, grouped under plain headings from its own section labels.

Read it on PubMed ↗

Obagi ZE, Balian RJ, Ramsey SV et al. Clinical Evidence of Skin Improvements With a Biologically Active Multimodal Topical Skin Treatment. Journal of drugs in dermatology : JDD. 2026. doi:10.36849/JDD.10086. PMID: 42696340. https://pubmed.ncbi.nlm.nih.gov/42696340/

Related research

AnimalsLab or animal study · Chemistry & biodiversity · Nov 20, 2026

Exploring Eugenia brasiliensis Leaves as a Natural Source for Anti-Aging, Skin Protection, and Phytocosmetic Applications.

The aim of this study was to evaluate the chemical composition and the in vitro anti-aging and skin-protective properties of the crude hydroalcoholic extract (CHE) and fractions of Eugenia brasiliensis, known as…

Study · bioRxiv : the preprint server for biology · Nov 20, 2026

Quantitative imaging of native tissue architecture combined with deep multi-omics reveals the spatial biology of kidney aging.

Aging alters tissue architecture and metabolism in spatially heterogeneous ways, yet the connections between these measurable structural and compositional phenotypes and underlying molecular changes are largely unknown.

AnimalsStudy · bioRxiv : the preprint server for biology · Nov 20, 2026

Aging exacerbates muscle loss induced by semaglutide treatment in female mice.

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, have transformed the pharmacological treatment of obesity.

Study · Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · Nov 20, 2026

A Multimodal Hyaluronic Acid Approach to Compensate Menopause-Related Skin Changes: Hyaluronic Acid Serum Subanalysis With HA Filler Injection.

BACKGROUND: Estrogen depletion during menopause reduces collagen, elastin, and glycosaminoglycans (GAG) synthesis, particularly hyaluronic acid (HA), and is associated with skin thinness, wrinkles, reduced elasticity,…

Summary of earlier studiesReview · Journal of cosmetic dermatology · Nov 18, 2026

How skin cell changes drive different kinds of skin aging

This review looks at how dermal fibroblasts, the cells that build skin support, may cause wrinkles, sagging, scarring, and other skin aging. It suggests some skin creams might target these cell changes.

Summary of earlier studiesReview · Journal of cosmetic dermatology · Nov 18, 2026

Collagen pills may improve skin moisture and stretch, but wrinkle results are unclear

A review of 35 trials found better skin water and elasticity with collagen. Wrinkle and skin density gains did not hold up in the checks, so they are not yet proven.

See all research on GLP-1 drugs →

Report a problem